Upload
dangliem
View
220
Download
0
Embed Size (px)
Citation preview
Regulation on
Clinical Trials in
Peru
Hans Vásquez, MD
General Directorate of Drugs and
Medical Device (DIGEMID)
Ministry of Health
Lima-Peru
Sao Paulo, Oct 2013
General Health Law
Law N°26842
July 1997
Law N°29316
January2009
Law N°29459
Nov 2009
SupremeDecree N°016-2011
July 2011
Timeline of new regulations
• Actually, this article is changed by new
regulations.
• Past regulation (until 2009):
- Legal time to approve new medicine (including
biological product) was 7 days.
- Requirements: some information of quality and no
evidence of efficacy and safety.
General Health Law.
Article 50 in Law N°26842
General Health Law
Law N°26842
July 1997
Law N°29316
January2009
Law N°29459
Nov 2009
SupremeDecree N°016-2011
July 2011
Timeline of new regulations
• This Law was created in the framework of
“United States-Peru Trade Promotion
Agreement.”
• Modify article 50 of General Health Law and
other aspects related to commerce aspects.
• Establish new requirements to approve new
medicine.
• Is the first time, that we have requirements of
efficacy and safety.
Law N° 29316
General Health Law
Law N°26842
July 1997
Law N°29316
January2009
Law N°29459
Nov 2009
SupremeDecree N°016-2011
July 2011
Timeline of new regulations
• Law of pharmaceutical product, medical device
and sanitary products.
• Establish new requirements to approve
pharmaceutical products (including biological
products), and medical device.
• Establish principles to evaluation of quality,
efficacy and safety.
- Efficacy: supported by preclinical and clinical trials.
- Safety: supported by adverse events in clinical trials
and other information.
Law N° 29459
PharmaceuticalProducts
Medicines(chemicalsynthesis)
Herbal Medicines
Dieteticproducts
Galenicproduct
Biologicalproduct
Law N° 29459
Pharmaceutical Products
General Health Law
Law N°26842
July 1997
Law N°29316
Enero 2009
Law N°29459
Nov 2009
SupremeDecree N°016-2011
July 2011
Timeline of new regulations
• Define specific aspects of Law N° 29459.
• Describe general requirements for
pharmaceutical products and medical device.
• Describe requirements of clinical trials for
different types of pharmaceutical products.
Supreme Decree N° 016 – 2011 (1).
• Requirements of efficacy and safety for marketing
authorization:
1. Biological products: full data of preclinical and clinical studies.
2. Medicines of “List of essential medicine in Peru”: not require
clinical studies to support.
3. Medicines of reference country: “information” of safety and
efficacy.
4. Medicine with same active pharmaceutical ingredientes that
medicine from reference country and list of essential medicine,
require scientific support (clinical trials and/or bibliographic
information).
5. Medicine different to 2, 3 and 4: Full data of preclinical and
clinical studies.
6. Studies to demostrate therapeutic equivalence for copy product
based on Specific Directive.
Supreme Decree N° 016 – 2011 (2).
Clinical trials in marketing
authorization - Summary. Peru
Not requirements of clinical studies.
List of essential medicine
Information of efficacy and
safety.Reference country
Support of efficacyand safety.
Same API
Preclinical and clinical studies.
The others
Source: Law N° 29459 (2009) and DS 016-2011
Studies to demostratetherapeutic equivalence
• There are 2 Authorities involved in approval process of Clinical Trials
(CT):
1. National Institute of Health (Peru-NIH).
2. National Directorate of Drugs and Medical Device (Regulatory
Authority of Medicines). DIGEMID
• Total time for to approve a CT: 40 days (working/business days).
• Only can start a CT if have:
1. Document of approval of CT (Peru NIH).
2. Document of approval the importation of investigational products
(DIGEMID).
Clinical Trial authorization
Clinical trials authorization
Peru NIH DIGEMID
Au
tho
riza
tio
n
Investigator´s Brochure + Overview of protocol
Official decisión of investigational product safety. Binding to Peru NIH (30 working days)40 days (working days)
Importation
Peru-NIH
• Reception of submission
• Official document of approval clinical trial
• Review amendments or extension.
• Coordinate GCP inspection.
DIGEMID
• Technical opinion of safety of investigational product (binding
to Peru NIH)
• Importation of investigational product
• Approval compassionate use
Responsabilities
General Information
http://www.ins.gob.pe/portal/jerarquia/2/826/informacion-para-el-publico-en-general/jer.826
Public information of clinical trials
http://www.ins.gob.pe/portal/jerarquia/2/923/resumen-de-ensayos-clinicos-en-el-peru/jer.923
Information for investigators
http://www.ins.gob.pe/portal/jerarquia/2/827/informacion-para-los-investigadores/jer.827
National Register of clinical trials
http://www.ins.gob.pe/portal/jerarquia/2/924/ingreso-al-registro-nacional-de-ensayos-clinicos/jer.924
• Link between marketing authorization (MA) of medicines
and clinical trials authorization: bioequivalence,
biosimilar, pivotal studies required by DIGEMID for MA.
• One review process of DIGEMID of investigational
product. Actually there are two.
• Improve the capacity of Ethics Committes.
Some challenges to regulation of clinical
trials